Publications by authors named "Kunxia Hu"
Context: Re-yan-ning mixture (RYNM) is a new national drug approved by China's State Food and Drug Administration for the treatment of colds, simple pneumonia and acute bronchitis.
Objective: To determine the mechanism of action of RYNM in the treatment of bacterial pneumonia.
Materials And Methods: Using the network pharmacology approach, the multiple components, component candidate targets and multiple therapeutic targets of RYNM were screened and functionally enriched.
Background: The Corona Virus Disease 2019 (COVID-19) is a new acute respiratory infectious disease that has become a major global public health event. In China, the combination of Huashi Baidu Formula (HBF) and antiviral drugs is used in the clinical treatment of severe patients with new coronary pneumonia, but there is still a lack of evidence-based medical evaluation.
Methods: We search for research in PubMed/MEDLINE, China National Knowledge Infrastructure (CNKI), Wanfang Database, VIP Database, Cochrane Library, Embase, China Biomedical Database (CBM), and Chinese Science Citation Database (CSCD).
Article Synopsis
- The study focused on creating a dioscin nanosuspension (Dio-NS) that improves its solubility and effectiveness for oral administration, as well as evaluating its effects on liver protection.
- Researchers optimized manufacturing parameters and ingredient concentrations using specific experimental methods to achieve a nanosuspension with favorable particle size and stability.
- Findings showed that Dio-NS had better dissolution compared to other forms, and it effectively protected against liver damage in mice, similar to an established medication, suggesting potential for further research on how it is absorbed in the body.
[Preparation and evaluation of dioscin nanostructured lipid carriers].
Zhongguo Zhong Yao Za Zhi
October 2017
In this report, a heat and high-pressure homogenization method was used to prepare dioscin nanostructured lipid carriers, and the formulation of dioscin nanostructured lipid carriers was optimized by central composite design-response surface methodology. In vitro evaluation data showed that the preparation of dioscin nanostructured lipid carriers under optimal process by central composite design-response surface methodology had a spherical shape and homogeneous size distribution, with a particle size of (90.9±0.
View Article and Find Full Text PDF